News | September 15, 2010

Ultrasound Breast Cancer Screening Gains Approval in EU

September 15, 2010 — Approval has been given to market the somo•v automated breast ultrasound system (ABUS) as an adjunct to mammography for screening asymptomatic women for breast cancer in the European Union. Approval was based on extensive clinical evidence and includes the following indication: “The intended use of the somo•v ABUS system is to provide a significant increase in breast cancer detection and sensitivity of interpreting physicians in diagnosing symptomatic and screening asymptomatic women as an adjunct to mammography.”

U-Systems' somo•v ABUS now has CE mark approval for breast cancer screening and is the first and only approved automated ultrasound system for screening asymptomatic women. The company notes that several studies have demonstrated a need for additional tools to improve the early detection of breast cancer, particularly in women with dense breast tissue.

“The somo•v ABUS is not intended as a replacement for mammography, which remains the most effective screening tool for many women," said Ron Ho, president and CEO of U-Systems. "However, we have strong scientific evidence that for women with dense breast tissue, supplementing mammograms with somo•v ABUS can substantially increase breast cancer detection.”

“The sensitivity of screening mammography is limited in women with dense breasts, as low as 30-50%,” said László Tabár, M.D., FACR (Hon) professor of radiology, Uppsala University School of Medicine, and Medical Director at the Department of Mammography Falun Central Hospital, Falun, Sweden. “It is essential to have a multimodality screening approach for detecting breast cancer at an early stage to prevent women from dying from this disease. The somo•v automated breast ultrasound system fulfills this important need in the multimodality approach.”

U-Systems is currently sponsoring the SOMO•INSIGHT clinical study, designed to evaluate whether digital mammography in combination with the somo•v system is more sensitive than a routine screening mammogram alone in detecting breast cancer in women with greater than 50 percent dense breast tissue. To date, more than 9,000 women have participated in the study, which is actively recruiting up to 20,000 women at multiple breast imaging centers in the United States.

The SOMO·INSIGHT clinical study has identified a significant number of mammographically negative breast cancers that would not have been detected had the participants not had an ABUS exam.

For more information: www.somoinsightstudy.org

Related Content

Early diagnosis of cancer is one of the highest-priority problem for the healthcare system, because it is critical for overall treatment success and saving patients' lives. Diffusion-weighted magnetic resonance imaging (DWI) may be used to detect a malignancy in various tissues and organs. It has the advantage of providing insight into the diffusion of water molecules in body tissues without exposing patients to radiation.

DWI of the phantom with polyvinylpyrrolidone (PVP) solutions (b value 500 s/mm2). Image courtesy of Kristina Sergunova et al.

News | Magnetic Resonance Imaging (MRI) | June 02, 2020
June 2, 2020 — Early diagnosis of cancer is one of the highest-priority problem for the healthcare system, because it
Developed by medical AI company Lunit, Software detects breast cancer with 97% accuracy; Study in Lancet Digital Health shows that Lunit INSIGHT MMG-aided radiologists showed an increase in sensitivity

Lunit INSIGHT MMG

News | Artificial Intelligence | June 02, 2020
June 2, 2020 — Lunit announced that its artificia...
The FDA has approved Lilly’s TAUVID (flortaucipir F 18 injection), a radioactive diagnostic agent, for PET imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease

Getty Images

News | Contrast Media | June 01, 2020
June 1, 2020 — TAUVID, a radioactive diagnostic agent, has been approved by the FDA for...
MERCK and RefleXion Medical announced a collaboration to evaluate KETRUDA (immunotherapy) with biology-guided radiotherapy - BgRT -  a new radiation machine developed to treat all stages of cancer.

MERCK and RefleXion Medical announced a collaboration to evaluate KETRUDA (immunotherapy) with biology-guided radiotherapy - BgRT -  a new radiation machine developed to treat all stages of cancer.

 

News | Radiation Therapy | June 01, 2020
June 1, 2020 — RefleXion Medical, a therape
AI has the potential to help radiologists improve the efficiency and effectiveness of breast cancer imaging

Getty Images

Feature | Breast Imaging | May 28, 2020 | By January Lopez, M.D.
Headlines around the world the past several months declared that...
United Imaging's uMR OMEGA is designed to provide greater access to magnetic resonance imaging (MRI) with the world’s first ultra-wide 75-cm bore 3T MRI.
News | Magnetic Resonance Imaging (MRI) | May 27, 2020
May 27, 2020 — United Imaging's...
Technology becomes a state-of-the-art tool when it gets exposed to a structure that constantly tests it and allows it to evolve.

Technology becomes a state-of-the-art tool when it gets exposed to a structure that constantly tests it and allows it to evolve. Getty Images

Feature | Oncology Information Management Systems (OIMS) | May 27, 2020 | By Reshu Gupta
In the history of medicine, researchers have found cures for many diseases, but cancer has been elusive.